Erythropoietin protects the subventricular zone and inhibits reactive astrogliosis in kaolin-induced hydrocephalic rats

Suryaningtyas, Wihasto; Arifin, Muhammad; Rantam, Fedik Abdul; Bajamal, Abdul Hafid; Dahlan, Yoes Prijatna; Ugrasena, I Dewa Gede; Maliawan, Sri

doi:10.1007/s00381-019-04063-w

Cited by 11 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erythropoietin (Epo), a hormone involved in erythropoiesis, has been shown to be a potent neuroprotective agent with anti-apoptotic, anti-inflammatory, and neurotrophic properties which also helps to decrease free iron and improve neurodevelopmental outcomes [ 106 ]. In a kaolin-induced rat model of hydrocephalus, recombinant human Epo was found to reduce the progression of hydrocephalus, decrease microglial activation, and astrogliosis [ 107 ]. Additionally, in a rat model of acquired PHH, Epo therapy in combination with melatonin was shown to decrease macrocephaly and ventriculomegaly, as well as prevent matted and missing ependymal cilia, decrease astrogliosis, and increase performance on a neurobehavioral test [ 71 ].…”

Section: Resultsmentioning

confidence: 99%

Hydrocephalus: historical analysis and considerations for treatment

2022

View full text Add to dashboard Cite

Hydrocephalus is a serious condition that affects patients of all ages, resulting from a multitude of causes. While the etiologies of hydrocephalus are numerous, many of the acute and chronic symptoms of the condition are shared. These symptoms include disorientation and pain (headaches), cognitive and developmental changes, vision and sleep disturbances, and gait abnormalities. This collective group of symptoms combined with the effectiveness of CSF diversion as a surgical intervention for many types of the condition suggest that the various etiologies may share common cellular and molecular dysfunctions. The incidence rate of pediatric hydrocephalus is approximately 0.1–0.6% of live births, making it as common as Down syndrome in infants. Diagnosis and treatment of various forms of adult hydrocephalus remain understudied and underreported. Surgical interventions to treat hydrocephalus, though lifesaving, have a high incidence of failure. Previously tested pharmacotherapies for the treatment of hydrocephalus have resulted in net zero or negative outcomes for patients potentially due to the lack of understanding of the cellular and molecular mechanisms that contribute to the development of hydrocephalus. Very few well-validated drug targets have been proposed for therapy; most of these have been within the last 5 years. Within the last 50 years, there have been only incremental improvements in surgical treatments for hydrocephalus, and there has been little progress made towards prevention or cure. This demonstrates the need to develop nonsurgical interventions for the treatment of hydrocephalus regardless of etiology. The development of new treatment paradigms relies heavily on investment in researching the common molecular mechanisms that contribute to all of the forms of hydrocephalus, and requires the concerted support of patient advocacy organizations, government- and private-funded research, biotechnology and pharmaceutical companies, the medical device industry, and the vast network of healthcare professionals.

show abstract

Section: Resultsmentioning

confidence: 99%

Hydrocephalus: historical analysis and considerations for treatment

2022

View full text Add to dashboard Cite

show abstract

“…AQP4, aquaporin 4. Suryaningtyas et al, 2019). EPO might decrease the expression of miR-130a and increase the expression of miR-668 (Rizwan Siddiqui et al, 2018).…”

Section: Therapeutic Targeting Of Astrocytes For the Treatment Of Hyd...mentioning

confidence: 99%

Novel therapeutic modulators of astrocytes for hydrocephalus

Yang

Wang²,

Chen³

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Hydrocephalus is mainly characterized by excessive production or impaired absorption of cerebrospinal fluid that causes ventricular dilation and intracranial hypertension. Astrocytes are the key response cells to inflammation in the central nervous system. In hydrocephalus, astrocytes are activated and show dual characteristics depending on the period of development of the disease. They can suppress the disease in the early stage and may aggravate it in the late stage. More evidence suggests that therapeutics targeting astrocytes may be promising for hydrocephalus. In this review, based on previous studies, we summarize different forms of hydrocephalus-induced astrocyte reactivity and the corresponding function of these responses in hydrocephalus. We also discuss the therapeutic effects of astrocyte regulation on hydrocephalus in experimental studies.

show abstract

“…In other studies, the combination of acetazolamide and furosemide has been found to be ineffective in reducing shunt placement and is associated with increased neurological morbidity [136,137]. [138]. Other drugs that target AQPs, such as erythropoietin, have shown good results in animal models of hydrocephalus [12,139].…”

Section: Non-surgical Treatmentmentioning

confidence: 99%

Hydrocephalus after aneurysmal subarachnoid hemorrhage: Epidemiology, Pathogenesis, Diagnosis, and Management

2021

View full text Add to dashboard Cite

Hydrocephalus is one of the most common complications of aneurysmal subarachnoid hemorrhage (aSAH), which seriously affects the quality of life and shortens the survival time of affected patients. By reviewing the recent studies on the risk factors of aSAH-associated hydrocephalus, we aimed to explicitly present the pathogenesis of acute and chronic hydrocephalus after aSAH and make a comprehensive list of the associated risk factors of aSAH-associated hydrocephalus and shunt-dependent hydrocephalus. It would help us to better explain the occurrence of hydrocephalus after aSAH, especially hydrocephalus caused by inflammation after bleeding. Many studies have recently suggested that high mobility group box 1 may be an early upstream promoter of inflammatory response after aSAH, which also provides important ideas for us to look for potential drug treatments. The surgery, such as external ventricular drain and lumbar drainage, is the most common and effective treatment. Yet, there are often complications, such as rebleeding and intracranial infection, and the optimal timing of intervention is controversial. Besides, this is also a systematic review of the recent advances in epidemiology, pathogenesis, diagnosis, and management of aSAH-associated hydrocephalus.

show abstract

Erythropoietin protects the subventricular zone and inhibits reactive astrogliosis in kaolin-induced hydrocephalic rats

Cited by 11 publications

References 46 publications

Hydrocephalus: historical analysis and considerations for treatment

Hydrocephalus: historical analysis and considerations for treatment

Novel therapeutic modulators of astrocytes for hydrocephalus

Hydrocephalus after aneurysmal subarachnoid hemorrhage: Epidemiology, Pathogenesis, Diagnosis, and Management

Contact Info

Product

Resources

About